BIOIDENTICAL HORMONE REPLACEMENT THERAPY

Bioidentical Hormone Replacement Therapy

Bioidentical Hormone Replacement Therapy

BHRT, or Bioidentical Hormone Replacement Therapy, is a treatment approach that involves using hormones that are chemically identical to those produced by the human body to address imbalances or deficiencies. This therapy is often used to treat symptoms related to hormonal changes, such as menopause, andropause, or other hormone-related conditions.


During menopause, the body undergoes significant hormonal changes, particularly a decline in estrogen and progesterone production, which can lead to a variety of physical and emotional symptoms.


Key points about BHRT include:


Bioidentical hormones are derived from plant sources and are designed to replicate the molecular structure of hormones naturally produced in the body. This is in contrast to synthetic hormones, which have a different chemical structure.


BHRT is used to alleviate a range of symptoms associated with hormonal imbalances, such as hot flashes, night sweats, fatigue, mood swings, and reduced libido.


Bioidentical hormones can be administered in various forms, including creams, gels, patches, injections, pellets or oral capsules, based on the individual's needs and preferences.


Regular monitoring of hormone levels and symptom assessment is crucial to ensure the effectiveness and safety of BHRT. Adjustments to the treatment plan may be made based on the ongoing evaluation of hormone levels and symptom relief.


If you are experiencing any of the following, contact us today:

  • Brain fog
  • Fibromyalgia/Body aches
  • Thyroid issues
  • PCOS
  • Feeling “tired but wired”
  • Irregular menstrual cycles
  • Low libido/Sexual Dysfunction/Vaginal Dryness
  • Feeling sluggish/Excessively fatigued/Difficulty falling asleep
  • Depression/Anxiety
  • Hot Flashes/Mood swings/ irritability
  • Feeling generally unwell despite your labs being “normal”
Book Now

References Addressing Safety:

1. Chlebowski, A et al. Menopausal Hormone Therapy Influence on Breast Cancer Outcomes in the Women’s Health Initiative. J Natl Compr Canc Netw, 2015 Jul;13(7):917-24.

2. Pinkerton, JV. Reassuring data regarding the use of estrogen therapy at the menopause. Menopause: The Journal of The North American Menopause Society, 2022, Vol. 29, No. 9, pp. 1001-1004.

3. Lobo RA, et al. Back to the future: Hormone replacement therapy as part of a prevention strategy for women at the onset of menopause, Atherosclerosis, 2016 Nov;254:282-290.

4. Turner R, Kerber IJ. A theory of eu-estrogenemia: a unifying concept. Menopause, Vol. 24, No. 9, pp. 1086-1097.

5. Kim, YJ et al. Association between menopausal hormone therapy and risk of neurodegenerative diseases: Implications for precision

hormone therapy. Alzheimer’s Dement. 2021;7:e12174.

6. Blakemore J, Naftolin F. Aromatase: Contributions to Physiology and Disease in Women & Men. Physiology, 2016 June;(31) 258-269.

7. Zhao H, et al. Aromatase Expression and Regulation in Breast and Endometrial cancer. J Molecul Endocrinology, 2016 Jul;(1):R19-33.

8. Glaser RL, Dimitrakakis C. Beneficial Effects of T Therapy in Women by Menopause Rating Scale. Maturitas. 2011 Apr;68(4) 355-61.

9. Glaser RL, Dimitrakakis C. Testosterone Therapy in Women: Myths and Misconceptions. Maturitas, 2013 Mar;74(3):230-4.

10. NotelovitzM.Androgeneffectsonboneandmuscle.FertilityandSterility.2002Apr;77Suppl4:S34-41.

11. Savvas M, et al. Increase in bone mass after one year of estradiol and testosterone implants in post-menopausal women who

previously received long-term oral estrogens. Br J Obstet Gynecol. 1992, Sep;99(9):757-60.

12. DavisSR,Wahlin-JacobsenS.Testosteroneinwomen—theclinicalsignificance.LancetDiabetesEndocrinol.2015;3:980–92.

13. Turner A et al. Testosterone increases bone mineral density in female to male transsexuals: a case series of 15 subjects. Clin

Endocrinol (Oxf). 2004 November ; 61(5): 560–566.

14. VEBiancheVE.TheAnti-InflammatoryEffectsofTestosterone.TheJournaloftheEndocrineSociety,2018Oct22;3(1):91-107.

15. Bialek M. Neuroprotective Role of Testosterone in the Nervous System. Pol J Pharmacol, 2004, Sep-Oct;(5): 509-18.

16. BrittoR,etal.ImprovementoflipidprofileinpostmenopausalwomenusingEandTimplants.GynecEndocr,2012;28(10):767-769.

17. Worboys S, et al. Evidence That Parenteral [pellet implant] Testosterone Therapy May Improve Vasodilation in Postmenopausal Women Receiving Estrogen, Journal of Clinical Endocrinology & Metabolism, Volume 86, Issue 1, Jan 2001, 158–161.

18. Hofling, M, et al. Testosterone inhibits estrogen/progesterone-induced breast cell proliferation in postmenopausal women.

Menopause, The Journal of the North American Menopause Society, 2007, Vol 14(2)183-190.

19. Glaser RL, Dimitrakakis C. Reduced Breast Cancer Incidence in Women Treated with Subcutaneous Testosterone, or Testosterone with Anastrozole: A prospective, observational study. Maturitas 76 (2013) 342-349.

20. Glaser RL, Dimitrakakis C. Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study. Glaser et al. BMC Cancer (2019) 19:1271.

21. BoniC,etal.TherapeuticActivityofTestosteroneinMetastaticBreastCancer.AnticancerResearch,2014;34:1287-1290.

22. Traish AM, Gooren L. Safety of physiological testosterone therapy in women: lessons from female-to-male transsexuals (FMT)

treated with pharmacological testosterone therapy. J Sex Med. 2010 Nov;7(11):3758-64.

Share by: